| Autor: |
K, Amschler, S, Phillip, J, Mohr, D, Wilsmann-Theis, S, Poortinga, S, Gerdes, R, Mössner |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Dermatology online journal. 26(2) |
| ISSN: |
1087-2108 |
| Popis: |
Switching of biologic agents in treatment of plaque psoriasis is a common strategy. Only a few studies are available on switching between IL17A-blockers. In a retrospective study, we identified 22 psoriasis patients who, after failing secukinumab as a first IL17A-blocker received ixekizumab with an observation period of at least 24 weeks. At last observation 10/22 patients had a good response (PASI75 or PASIlt;3) using ixekizumab therapy. None of five patients with primary non-response to secukinumab reached a good, durable response to ixekizumab. In conclusion, ixekizumab appears to be a therapeutic option as a second IL17A-blocker in psoriasis patients who did not show a primary non-response to secukinumab. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
